MADIT -CRT: Increased survival with resynchronization therapy plus defibrillator in patients with mild heart failure.

The MADIT -CRT study (Multicenter Automatic Defibrillator Implantation with Cardiac Resynchronization Therapy) had shown that early intervention with cardiac resynchronization therapy plus defibrillator in patients with electrical block pattern of complete left bundle branch was associated with a significant reduction of events in a mean follow-up of 2.4 years compared with the defibrillation therapy only.In this study the effect on long-term survival (mean 5.6 years) of the MADIT -CRT populationwas evaluated.At follow-up end, the rate of death from any cause in patients receiving cardiac resynchronization therapy and defibrillation was 18% versus 29% of those randomized to defibrillation alone (p <0.001).Resynchronization therapy was not associated with any clinical benefit or harm even in patients without LBBB.

Conclusion

In patients with mild symptoms of heart failure, ventricular dysfunction and complete left bundle branch block, early intervention with cardiac resynchronization therapy plus defibrillation is associated with a significant survival benefit in the long term.

Article

6_ilan_goldenberg_slides
Ilan Goldenberg
2014-03-31

Original title: Long-term Survival with Cardiac Resynchronization Therapy in Patients with Mild Heart Failure.

More articles by this author

CORP-2 Trial: Colchicine effective in reducing the recurrence of pericarditis associated withconventional anti-inflammatory pattern.

Colchicine is effective in treating an acute pericarditis event and initial recurrences;however, there is no conclusive data on its efficacy and safety in the...

Melody

The ducts of the right ventricle to the pulmonary artery are used in approximately 20 % of all patients with congenital defects including tetralogy...

Negative ultrasensitive troponin T values may help discriminate patients with chest pain in the emergency

New laboratory tests can detect minimally elevated  levels few hours before regarding detection methodologies of previous generations.The hypothesis of this study is that patients...

LAPLACE 2: Evolocumab effective in reducing LDL associated with statins

There are several patients who do not reach recommended LDL cholesterol despite maximally tolerated doses of statins levels.The Evolocumab is a monoclonal antibody that...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...